Role of endogenous nitric oxide in the nitric oxide donor-induced plasma extravasation of mouse skin

European Journal of Pharmacology

Volumn 377, Issue 2-3, 1999, Pages 219-222

  Fujii, Emiko ^a   Wada, Keiji ^a   Ishida, Hiroyasu ^b   Yoshioka, Toshimasa ^a   Muraki, Takamura ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Nitric oxide; Nitric oxide (NO) donor; Prostaglandin; Vascular permeability

Indexed keywords

INDOMETACIN; N(G) NITRO DEXTRO ARGININE METHYL ESTER; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PROSTANOID; TRIAZENE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; EXTRAVASATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SKIN BLOOD VESSEL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CAPILLARY PERMEABILITY; COLORING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; INDOMETHACIN; MALE; MICE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; NITROSO COMPOUNDS; PLASMA; PROSTAGLANDINS; SKIN; TRIAZENES;

EID: 0032802675     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00436-7     Document Type: Article

References (21)

1. Baldwin A.L., Thurston G., Al Naemi H. Inhibition of nitric oxide synthesis increases venular permeability and alters endothelial actin cytoskeleton. Am. J. Physiol. 274:1998;H1776-H1784.
2. Campbell, W.B., Halushka, P.V., 1996. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Hardman, J.G., Gilamn, A.G., Limbird, L.E. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill, New York, pp. 601-616.
3. Cirino G. Multiple controls in inflammation. Biochem. Pharmacol. 55:1998;105-111.
4. Clancy R.M., Abramson S.B. Nitric oxide: a novel mediator of inflammation. Proc. Soc. Exp. Biol. Med. 210:1995;93-101.
5. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;113-122.
6. Fujii E., Irie K., Uchida Y., Tsukahara F., Muraki T. Possible role of nitric oxide in 5-hydroxytryptamine-induced increase in vascular permeability in mouse skin. Naunyn-Schmiedeberg's Arch. Pharmacol. 350:1994;361-364.
7. Fujii E., Irie K., Uchida Y., Ohba K., Muraki T. Role of eicosanoids but not nitric oxide in the platelet-activating factor-induced increase in vascular permeability in mouse skin. Eur. J. Pharmacol. 273:1995;267-272.
8. Fujii E., Irie K., Ogawa A., Ohba K., Muraki T. Role of nitric oxide and prostaglandins in lipopolysaccharide-induced increase in vascular permeability in mouse skin. Eur. J. Pharmacol. 297:1996;257-263.
9. Fujii E., Irie K., Ohba K., Ogawa A., Yoshioka T., Yamakawa M., Muraki T. Role of nitric oxide, prostaglandins and tyrosine kinase in vascular endothelial growth factor-induced increase in vascular permeability in mouse skin. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;475-480.
10. Holzer P., Jocič M., Peskar B.A. Mediation by prostaglandins of the nitric oxide-induced neurogenic vasodilatation in rat skin. Br. J. Pharmacol. 116:1995;2365-2370.
11. Hrabie J.A., Klose J.R., Wink D.A., Keefer L.K. New nitric oxide-releasing zwitterions derived from polyamines. J. Org. Chem. 58:1993;1472-1476.
12. Hughes S.R., Williams T.J., Brain S.D. Evidence that endogenous nitric oxide modulates oedema formation induced by substance P. Eur. J. Pharmacol. 191:1990;481-484.
13. Ikeda K., Nakamura T., Ohnuma T., Chow T., Satoh N. A pharmacokinetic study of a light-stable sodium nitroprusside, MR7S1. Yakuri to Chiryo (Jpn. Pharmacol. Ther.). 22:1994;3183-3195.
14. Kubes P., Granger D.N. Nitric oxide modulates microvascular permeability. Am. J. Physiol. 262:1992;H611-H615.
15. Kurose I., Kubes P., Wolf R., Anderson D.C., Paulson J., Miyasaka M., Granger D.N. Inhibition of nitric oxide production mechanisms of vascular albumin leakage. Circ. Res. 73:1993;164-171.
16. Mayhan W.G. Nitric oxide accounts for histamine-induced increases in macromolecular extravasation. Am. J. Physiol. 266:1994;H2369-H2373.
17. Mitchell D., Tyml K. Nitric oxide release in rat skeletal muscle capillary. Am. J. Physiol. 270:1996;H1696-H1703.
18. Noel A.A., Fallek S.R., Hobson R.W. II, Duran W.N. Inhibition of nitric oxide synthase attenuates primed microvascular permeability in the in vivo microcirculation. J. Vasc. Surg. 22:1995;661-669.
19. Sautebin L., Ialenti A., Ianaro A., Di Rosa M. Modulation by nitric oxide and prostaglandin biosynthesis in the rat. Br. J. Pharmacol. 114:1995;323-328.
20. Williams T.J., Morley J. Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature. 246:1973;215-217.
21. Zhang P., Ohara A., Mashimo T., Sun J., Shibata S., Takada K., Kosaka H., Terada M., Yoshiya I. Cardiovascular effects of an ultra-short-acting nitric oxide-releasing compound, zwitterionic diamine/NO adduct, in dogs. Circulation. 94:1996;2235-2240.